Evidence map›Paper›PMID 34101001›Full record

ArticleLangenbeck's archives of surgery2021

Malignant prediction in paragangliomas: analysis for clinical risk factors.

Miquel Torres-Costa, Benito Flores, Nuria Torregrosa, Miguel González, Antonio Ríos, Beatriz Febrero, Diego Flores, Pablo Rodríguez, Pablo Carbonell, María Isabel Ortuño and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in Langenbeck's archives of surgery, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
0.8field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 6 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Metastatic paraganglioma.BMJ case reports · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 1 country.

Miquel Torres-CostaDepartment of Surgery, Hospital Clínico Universitario Virgen de La Arrixaca, Murcia, Spain. torrescostamiquel@gmail.com.ORCID http://orcid.org/0000-0003-2027-9558
Benito FloresDepartment of Surgery, Hospital General Universitario Morales Meseguer, Murcia, Spain.
Nuria TorregrosaDepartment of Surgery, Hospital General Universitario Santa Lucía, Cartagena, Spain.
Miguel GonzálezDepartment of Surgery, Hospital Universitario Reina Sofía, Murcia, Spain.
Antonio RíosDepartment of Surgery, Hospital Clínico Universitario Virgen de La Arrixaca, Murcia, Spain.
Beatriz FebreroDepartment of Surgery, Hospital Clínico Universitario Virgen de La Arrixaca, Murcia, Spain.
Diego FloresDepartment of Surgery, Hospital General Universitario Morales Meseguer, Murcia, Spain.
Pablo RodríguezDepartment of Surgery, Hospital General Universitario Santa Lucía, Cartagena, Spain.
Pablo CarbonellCenter for Biochemistry and Clinical Genetics, Hospital Clínico Universitario Virgen de La Arrixaca, Murcia, Spain.
María Isabel OrtuñoDepartment of Pathology, Hospital Clínico Universitario Virgen de La Arrixaca, Murcia, Spain.
José Manuel RodríguezDepartment of Surgery, Hospital Clínico Universitario Virgen de La Arrixaca, Murcia, Spain.
Hospital Universitario Virgen de la Arrixaca · ESHospital General Universitario Morales Meseguer · ESSanta Lucía University General Hospital · ESHospital Universitario Reina Sofía · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionParagangliomas are infrequent neuroendocrine tumours whose only criterion for malignancy is presence of metastases; thus, all paragangliomas show malignant potential. Actually, different risk factors have been analyzed to predict metastases but they remain unclear. PURPOSE: To analyze clinical, histological, and genetic factors to predict the occurrence of metastasis. PATIENTS AND

methodA multicentre retrospective observational analysis was performed between January 1990 and July 2019. Patients diagnosed with paraganglioma were selected. Clinical, histological, and genetic features were analyzed for the prediction of malignancy.

resultsA total of 83 patients diagnosed with paraganglioma were included, of which nine (10.8%) had malignant paraganglioma. Tumour size was greater in malignant tumours than in benign (6 cm vs. 4 cm, respectively; p = 0.027). The most frequent location of malignancy was the thorax-abdomen-pelvis area observed in six cases (p = 0.024). No differences were observed in histological differentiation, age, symptoms, and catecholaminergic production. The most frequent genetic mutation was SDHD followed by SDHB but no differences were observed between benign and malignant tumours. In the univariate analysis for predictive factors for malignancy, location, tumour size, and histological differentiation showed statistical significance (p = 0.025, p = 0.014, and p = 0.046, respectively); however, they were not confirmed as predictive factors for malignancy in the multivariate analysis.

conclusionIn this study, no risk factors for malignancy have been established; therefore, we recommend follow-up of all patients diagnosed with paraganglioma.

Indexed as

Adrenal Gland NeoplasmsParagangliomaPheochromocytomaHumansRetrospective StudiesRisk FactorsSuccinate DehydrogenaseSuccinate DehydrogenaseFollow-upMalignant paragangliomaRecurrenceRisk factors

Identifiers

PMID34101001
OpenAlexW3170682749

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.